Co-Diagnostics, Inc. Net Change in Cash
Co-Diagnostics, Inc. (CODX) reported Net Change in Cash of -$8.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-13
- Co-Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$3.65M.
- Co-Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$1.03M, a 112.63% decline year-over-year.
- Co-Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $8.18M.
- Co-Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$16.61M, a 288.49% decline year-over-year.
- Co-Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $8.95M.
- Co-Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$11.98M.
- Co-Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$8.06M.
- Co-Diagnostics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$65.63M, a 243.84% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.23M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$3.65M 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $8.95M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $8.51M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $8.18M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$1.03M 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | -$11.98M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$4.12M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$1.06M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $8.18M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$8.06M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$12.73M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$9.14M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$16.61M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$65.63M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | -$7.10M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$2.56M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $8.81M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $45.63M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $39.68M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $27.30M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $14.81M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $42.08M 10-K · filed 2022-03-24 | |||
| 2020-09-30 | $20.34M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $17.66M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $16.48M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$57.10K 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $1.59M 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | $2.91M 10-Q/A · filed 2020-11-03 | |||
| 2019-03-31 | $4.46M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$2.58M 10-K · filed 2020-03-30 | |||
| 2018-09-30 | -$1.36M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | -$2.01M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |